Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist drug, FDA-approved for type 2 diabetes mellitus (Ozempic and Rybelsus) and chronic weight management (Wegovy)
This article explores how GLP-1 medications affect metabolism, who may benefit from treatment, and important safety considerations for UK patients
Established thrombotic risk factors commonly present in semaglutide users include: Obesity (BMI 30 kg/m), which increases VTE risk 2-3 fold [13] Type 2 diabetes and insulin resistance Prolonged immobility or sedentary lifestyle History of previous blood clots Active cancer or recent cancer treatment Recent surgery, particularly orthopedic or abdominal procedures Smoking Certain medications, including estrogen-containing contraceptives or hormone replacement therapy Inherited thrombophilias (clotting disorders) Advanced age (risk increases after age 60) Pregnancy and postpartum period (note that semaglutide should be discontinued when pregnancy is recognized) Patients initiating semaglutide should undergo comprehensive baseline assessment including medical history review, with particular attention to prior thrombotic events and family history of clotting disorders
Hygiene is essential
How to Use L-Carnitine and Precautions Using L-Carnitine the right way ensures you unlock every benefit it offers
Read Blog Can You Do Laser Hair Removal While Pregnant
